{"ticker": {"uuid": "c22df54b-1fd5-4654-a5de-2e14d3453d20", "symbol": "OLMA", "name": "Olema Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why", "summary": "Olema Pharmaceuticals (NASDAQ:OLMA) saw its shares increase by 5.9% on Friday, trading at $11.7270 on lighter than usual volume. Analysts have a mixed but generally positive sentiment towards the stock, with a consensus \"Moderate Buy\" rating and a target price of $44.10. The comp", "url": "https://www.marketbeat.com/instant-alerts/olema-pharmaceuticals-nasdaqolma-shares-up-59-heres-why-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T17:40:34", "published_display": "17 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to \"Sell\"", "summary": "Wall Street Zen has upgraded Olema Pharmaceuticals (NASDAQ:OLMA) from \"strong sell\" to \"sell.\" Despite this upgrade, the overall analyst consensus from MarketBeat remains a \"Moderate Buy\" with an average price target significantly higher than the current trading price. The articl", "url": "https://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-olema-pharmaceuticals-nasdaqolma-to-sell-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T18:09:45", "published_display": "12 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article displays financial data for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) focusing on its enterprise value to EBIT forward. The content is primarily a data presentation, indicating market status as closed with no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T14:39:15", "published_display": "10 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article provides financial information for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data snippet from TradingView, indicating no current trading activity for the stock. The article li", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T12:11:45", "published_display": "10 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Olema Pharmaceuticals, Inc. \u2013 BOATS:OLMA", "summary": "The article displays the \"Price to earnings forward\" metric for Olema Pharmaceuticals, Inc. (OLMA) on the TradingView platform. It provides financial data and indicates that the market was closed with no trades. The content primarily shows navigation elements and structural infor", "url": "https://www.tradingview.com/symbols/BOATS-OLMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T11:39:15", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Jefferies London Healthcare Conference 2025 Summary", "summary": "Olema Pharmaceuticals (OLMA) presented at the Jefferies London Healthcare Conference 2025, highlighting its focus on ER-positive, HER2-negative breast cancer with lead asset palazestrant currently in two pivotal Phase III trials (OPERA-01 and OPERA-02). The company also discussed", "url": "https://quartr.com/events/olema-pharmaceuticals-inc-olma-jefferies-london-healthcare-conference-2025_Feli00wb", "source_name": "Quartr", "published_at": "2026-07-08T20:43:51", "published_display": "08 Jul 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5nd2xWMl81MG5qc0wxeHVXSXZYQUc2N1RUNTBDb3BOWXIzYk9ybFlCY2YtWm9FT2w1RF9YWDg2Wk9wSnFCMWdkVnZ0MmxWQ1hVNHdpV0hEUnFEUEk?oc=5", "source_name": "ChartMill", "published_at": "2026-07-08T00:00:02+00:00", "published_display": "08 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "The article concerns the enterprise value to EBITDA forward metric for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). It appears to be a financial data snippet or a preliminary page from TradingView, indicating that specific financial data for this metric would be displayed. The con", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:41:13", "published_display": "07 Jul 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. \u2013 BOATS:OLMA", "summary": "This article provides financial information for Olema Pharmaceuticals, Inc. (OLMA), specifically focusing on its enterprise value to EBITDA forward. The data is presented within the TradingView platform, noting that the market is closed and no trades have occurred for the company", "url": "https://www.tradingview.com/symbols/BOATS-OLMA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:39:44", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article provides a specific financial metric, \"Enterprise value to revenue forward,\" for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). It indicates that the value for this metric is currently unavailable or not specified, only noting the period, value, change, and percentage c", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:11:54", "published_display": "06 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article provides financial information for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), focusing on its forward price to sales metric. It highlights that the data for this financial indicator is contributed by human analysis, suggesting a qualitative aspect to the valuation. ", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T06:10:06", "published_display": "06 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24", "summary": "LifeSci Capital has reiterated its Buy rating for Olema Pharmaceuticals (OLMA.US), maintaining a target price of $24. This indicates continued confidence from the firm in the company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/72419265/lifesci-capital-maintains-olema-pharmaceuticals-olmaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-03T06:39:44", "published_display": "03 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that it granted stock options to eight new employees to purchase 215,800 shares of common stock, effective July 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listi", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377819", "source_name": "The Manila Times", "published_at": "2026-07-03T05:40:16", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?", "summary": "Olema Pharmaceuticals (OLMA) has been added to several Russell growth benchmarks, increasing its visibility to institutional investors. Despite a recent mix of share price volatility, the company's valuation, based on a discounted cash flow model, suggests it is significantly und", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-olema-pharmaceuticals-olma-a-bargain-after-its-russell-in", "source_name": "Simply Wall Street", "published_at": "2026-07-03T01:40:46", "published_display": "03 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology awards 215,800 options to eight new employees", "summary": "Olema Oncology (Nasdaq: OLMA) announced it granted stock options to eight new employees to purchase an aggregate of 215,800 shares of common stock, effective July 1, 2026. These inducement awards were made under its 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635", "url": "https://www.stocktitan.net/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-lcfevi8yty7j.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:46", "published_display": "02 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index Inclusion - Has The Bull Case Changed?", "summary": "Olema Pharmaceuticals (OLMA) has seen a 22% stock increase following its inclusion in multiple Russell Growth Benchmarks, including the Russell 2000, 2500, and 3000 indices. While this inclusion boosts visibility and trading liquidity, the company's investment narrative remains f", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/olema-pharmaceuticals-olma-is-up-220-after-broad-russell-gro", "source_name": "Simply Wall Street", "published_at": "2026-07-01T04:09:20", "published_display": "01 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPcTJmZFN1LUItQlFqTm5qVTMtZTdtVmtzWGh0R1R1UEcwc05wLVlTMkZNS0ZCeW5BM3V6RUF6UF9kQmhUUEl0bVV2UmY1TThtMl9ickx3SC1sUjBMYjg1QkI1Q19xZ3ZLUlBZYWlNWk5lcGRVeC0xRnlUNlVfb05ZMHZBTDk0X2RaUE95RnQwSXRhMm96ZUNITU1tdjJrTnJQMzVHOQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Olema Pharmaceuticals, Inc. (NasdaqGS:OLMA) has been added to the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent developments for the company, including presentations at healthcare conferences and clinical trial collaborations for its experimental ca", "url": "https://www.marketscreener.com/news/olema-pharmaceuticals-inc-nasdaqgs-olma-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc8bf723", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:13:00", "published_display": "29 Jun 2026 17:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA)", "summary": "This article provides an overview of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, key financial metrics, and company information. The article also answers ", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:35", "published_display": "26 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OLMA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Olema Pharmaceuticals, Inc. (OLMA) has a current stock price of $11.43, with analysts providing a 1-year price forecast ranging from $23.00 to $62.00, and a consensus target of $40.70. The company's stock has seen significant volatility, with a 143.71% increase over the last year", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:35", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51", "summary": "Olema Pharmaceuticals director Harmon Cyrus was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options vest in 12 equal monthly installments beginning June 18, 2026, contingent on continued service, or fully vest at the next", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-ba93150fbec9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:40:35", "published_display": "24 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51", "summary": "Olema Pharmaceuticals director Graham G. Walmsley was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments beginning June 18, 2026, or fully on the date of Olema's next annual sto", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-63bb7cde30f0.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:12:07", "published_display": "24 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young", "summary": "Olema Pharmaceuticals (NASDAQ: OLMA) stockholders approved the election of four Class III directors, an advisory executive compensation program, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year at their annual", "url": "https://www.stocktitan.net/sec-filings/OLMA/8-k-olema-pharmaceuticals-inc-reports-material-event-985158c2578c.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:12:07", "published_display": "24 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price", "summary": "Olema Pharmaceuticals director Cynthia M. Butitta was granted 29,500 stock options at an exercise price of $9.51 per share. These options serve as compensation and will vest in 12 equal monthly installments starting June 18, 2026, provided she continues her service. Any unvested ", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-a16d317b5516.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:12:07", "published_display": "24 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (OLMA) director receives 29,500 options at $9.51 strike price", "summary": "Olema Pharmaceuticals director Sandra Horning was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments starting June 18, 2026, contingent on her continuous service, with any unves", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-1d03cac55e35.html", "source_name": "Stock Titan", "published_at": "2026-06-24T01:09:50", "published_display": "24 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51", "summary": "Olema Pharmaceuticals director Garland J. Scott was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. These options vest in 12 equal monthly installments starting June 18, 2026, contingent on Scott's continuous service. This grant ", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-303ea7dcb677.html", "source_name": "Stock Titan", "published_at": "2026-06-24T01:09:50", "published_display": "24 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price", "summary": "Olema Pharmaceuticals director Andrew Rappaport was granted 29,500 stock options at an exercise price of $9.51 per share, as part of his compensation. These options, which expire on June 18, 2036, vest in 12 equal monthly installments starting June 18, 2026, or fully on the next ", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-0651621136c6.html", "source_name": "Stock Titan", "published_at": "2026-06-24T01:09:50", "published_display": "24 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com", "summary": "This article announces the filing of Form 4 for Olema Pharmaceuticals Inc. on June 23. It notes that the company's stock, OLMA, showed a 5.79% increase and includes various financial market data and related news. The content is primarily a brief announcement paired with general m", "url": "https://ng.investing.com/news/stock-market-news/form-4-olema-pharmaceuticals-inc-for-23-june-93CH-2571070", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T22:32:00", "published_display": "23 Jun 2026 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNaWpsU0VycWdrSmtfblhZa3BPLTY1aUJOTkVXRUkzM2xiNUlvYnhCcG5ha1REeFRBYUltUXRqd3RyVVZrZ1V5VEhKV2hjNUwweUY2SUUxNFduTFIyQmp4WnBEb0pIQWVNUmN0cDZtbENmWXNNZ0NXQlQ0V04xUm9tVURyczlMN1M1aUNOUXZRcE16eEpyTENMUFBjekxRZ29iQklJbHJWbUZCcTEtSE51aHQ3d0R1Znlvd0dV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (NASDAQ: OLMA) awards director 29,500 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeDFiTjFCS3ZuT1N2MXJ3UHQ0eHFXVWNLcGp0NmRSQzMzN2xuRlJVV1dZVnM3TTZ4UkR1czhZUzA5Vmt0aVpqWEpacHp4ZFV2c2hhZnp3VzBaWFN6SW9sU05iUDdnbFYzZUp1UXVNSlZYREJBWUtabXhhZ3pjRmxxamxiWnhsYWRjMWNla2JNb2U0TFFyY1JjN2QtVkVKM0Z4WFl0eEpKb3p2Q1Vaa3VMWGtFMDdza29IbjJZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbFBjNkNwc2laMnp5U3Q5YTBwclRpMjEyTzNoOU9jek9WVEZROEt6b2NSbXBVYkpabEFjVU1Ed2YtZnlfOTNHb3dBOFA4R01pSGhOWjF0MkVmeXEzVVdGeGR4T2hrSkI0NFhHWlphMy1lSTNJM1BONmpCTjkzeGZwVEloc1JEUDZfRE9hV2tCSVVDNTBtVi1ESUlHallOaDJ4aGpoU2lR?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-pharmaceuticals-bayer-collaborate-test-115457083.html", "source_name": "MT Newswires", "published_at": "2026-05-26T11:54:57+00:00", "published_display": "26 May 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA\u00ae (darolutamide) in Metastatic Castration-Resistant Prostate Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-oncology-announces-clinical-trial-110000261.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema\u2019s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-op-3136-data-draw-190553267.html", "source_name": "Simply Wall St.", "published_at": "2026-05-25T19:05:53+00:00", "published_display": "25 May 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study", "summary": "", "url": "https://finance.yahoo.com/m/bc714b6d-d579-325f-926d-86b16217feaa/olema-oncology-sees-early.html", "source_name": "Stocktwits", "published_at": "2026-05-22T13:06:31+00:00", "published_display": "22 May 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-oncology-announces-encouraging-initial-210000497.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:00:00+00:00", "published_display": "21 May 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-oncology-participate-upcoming-investor-203000735.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:30:00+00:00", "published_display": "19 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema: The Market Overreacted To Roche's SERD Failure", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQT214czFUb1hzdURyZVRwRnZBZWItLXVIZDRGbDFpOFJQb3Y1TG80NHhacmRUcVRsdXZNRGd1ZmFLU0lzR28wcWdQT3p0SGFSY2FBSEoxV1NtbzdIOFdUM0ZnV3IyWGxtRWZ4N0hOQUZ2VEFuTmE0d2x4ZVZHZ3hqdnNuanVpWHJiWGVKeGFKX2xiOVAyWkxZ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdjB0TWhYaGVXczNnQkNiSzNHbmc0WG1maXRFeTBEWWwyMFVlZ2J2bExmallVZnR0YTgzN2NGOWZ2b0RpSXNGS3AzUTh4ZHJCN0xTZUcxRVZKeUlhTS1IQzFiMXUwb3NQcDVYeWhEQW5aUWJTc0xUbFk5eDR2bWNkQjVHeTFMc05oMV8tZEJITDg1TThMTllhZkdCeHcxMUFib2NxVE52dDdKZw?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQcnBMVkV2YXNJWTlvbE9ja0FMY0RnLThneUNFRDlRZzBDZEJCcE5xQmQ3NlZQZUxOMFBfX0ZnVUhpc3dRM2xWYUFKQXFrdnJHY29RdzBIQ1RWajFDSUlFaTk2aWJEbUJXZGNneGxpQW9XWVU3OHNPdUlIM0xIV0lTN2VtZmx3U1JW?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNdHJHQ2lpQ1U3cDN4V0ZVdk5FWTd0N0JPZnBueXNtLXBIMlFUa0VnMExnM0NBU09hX19qaDhjLTUxZ2dvZWpPSG9YODEwMjQ1VGZHWHU2TkdBUXJqdU9UWjF2VTRrNUF6OWhvX1BaMm85MUs4MVBNQWxNbG5iSWptcF9GOGFvTDBKa3pSakQ4Y2k?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After A 348% One\u2011Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQdFZWbXRZUEhtU3ZrRlk3cmp6VHd0V0FmM3RzaHo5NzV2MTEtWjdNa01rYWhDNkxxSmZKNW1sSVFyTWJLalNfWWVBRU9YQTNwRlh5ajM2RC02cHdaNEtqcnFYa2YzZDNqY0VUajRjeEhDd0t3Q3ZkQnQzQTROVFVaQ0ZwRDA2anlILThIcjFB?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTUZCSjYtVGN3dXFENk4yNkxFTzRhYnZVRDN5VWdwSmstZFktWmwySlIwSmV0OFIxWmQtQy1hMmZqcFdhaHF6RnB3b0QyMmtYU2pJTFNaWU9UOFo1WTU2OVVlRVFGTktTbmNzNTZwbi1adXQ3cEVPQS1LQ3NVM3dJa1lnYzd6aGY3al9oWXNnZWo5aVdibHczOW5R?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPQ2xVdzJaNEZIb0FDSk1Bdmg2UFUzRXFJTU1wT216YVRpVkVQRnR3THYteEZtb1ZVSGtFcUUzaHo5SEl6Y1JCWjQzd3d4YU1jMFc0a3ZiWEVDNVl3a0pTMlQ4eFdfVFRjemVXLU92ZTZPMmQ0Nm5FMG13Uk9IRUEzamdJTTdxMDYzOWc?oc=5", "source_name": "Market source", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals Plans Public Offering of Common Stock to Support Breast Cancer Therapy Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQOG9vZENyV0NDMHJpeFhhUXhfV2dWZzAzdkUzZnUzWG42ZEM5UDRvTzQxdTFWY1drdkJPdm4wTUVmTXhiU2xPNWhtVHlPTVZzV3czUU4zRmw2MV9KNFMwRDVYb3k3NV9nRHBSTDAtV2tNaS1fbnpNR2llS005ZlUwSTZmOTVRbXN0cTVMZ2UxZ3ZXbThlNzRKaC1vZFNzbmlIT3FQZ045U2ZoWkJycFlaZVZYNHZrdWh3RDRrOVdQNmlTZy12VDhIaWxnNGZ0WVNPcWZJ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceutical CEO Sean Bohen on the fight to end breast cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNbTVhZERVSzhwMGkxYXJoUWtkUFlhemFYMWgyRnlOdEVpOVBhOU5Md24zYmN3bXVia0VIMWRGM0JfWFBldjhJQ1BSLXg3Y3F6X01DZmF6VUNxRkIxcS1YaDlfdWl2dm5fRVo2d1BYSy0wQzB0X0tJempJTVc4NG42dUpCTFpkRjVESWc3TW1EbFc5Y1ZybXFtSG1JYlFUa1lVaXc2dzVVVWJZNGdaWGtfLUlB?oc=5", "source_name": "CNBC", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE82ek9WWTJlSE9XdHFKRWlQWHNGLUNnbFNiZnF0OFB0YlBwTlZUa3VMdVhUdWM5QTllQlY1MjJ6VmRGZzZTRGxvX1hmUmFjeWcxbHA4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:59:55+00:00", "published_display": "25 Apr 2025 01:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces New Clinical Trial Collaboration", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-12-02T08:00:00+00:00", "published_display": "02 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why", "summary": "Olema Pharmaceuticals (NASDAQ:OLMA) saw its shares increase by 5.9% on Friday, trading at $11.7270 on lighter than usual volume. Analysts have a mixed but generally positive sentiment towards the stock, with a consensus \"Moderate Buy\" rating and a target price of $44.10. The comp", "url": "https://www.marketbeat.com/instant-alerts/olema-pharmaceuticals-nasdaqolma-shares-up-59-heres-why-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T17:40:34", "published_display": "17 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to \"Sell\"", "summary": "Wall Street Zen has upgraded Olema Pharmaceuticals (NASDAQ:OLMA) from \"strong sell\" to \"sell.\" Despite this upgrade, the overall analyst consensus from MarketBeat remains a \"Moderate Buy\" with an average price target significantly higher than the current trading price. The articl", "url": "https://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-olema-pharmaceuticals-nasdaqolma-to-sell-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T18:09:45", "published_display": "12 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article displays financial data for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) focusing on its enterprise value to EBIT forward. The content is primarily a data presentation, indicating market status as closed with no trades.", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T14:39:15", "published_display": "10 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article provides financial information for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data snippet from TradingView, indicating no current trading activity for the stock. The article li", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T12:11:45", "published_display": "10 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Olema Pharmaceuticals, Inc. \u2013 BOATS:OLMA", "summary": "The article displays the \"Price to earnings forward\" metric for Olema Pharmaceuticals, Inc. (OLMA) on the TradingView platform. It provides financial data and indicates that the market was closed with no trades. The content primarily shows navigation elements and structural infor", "url": "https://www.tradingview.com/symbols/BOATS-OLMA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T11:39:15", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Jefferies London Healthcare Conference 2025 Summary", "summary": "Olema Pharmaceuticals (OLMA) presented at the Jefferies London Healthcare Conference 2025, highlighting its focus on ER-positive, HER2-negative breast cancer with lead asset palazestrant currently in two pivotal Phase III trials (OPERA-01 and OPERA-02). The company also discussed", "url": "https://quartr.com/events/olema-pharmaceuticals-inc-olma-jefferies-london-healthcare-conference-2025_Feli00wb", "source_name": "Quartr", "published_at": "2026-07-08T20:43:51", "published_display": "08 Jul 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5nd2xWMl81MG5qc0wxeHVXSXZYQUc2N1RUNTBDb3BOWXIzYk9ybFlCY2YtWm9FT2w1RF9YWDg2Wk9wSnFCMWdkVnZ0MmxWQ1hVNHdpV0hEUnFEUEk?oc=5", "source_name": "ChartMill", "published_at": "2026-07-08T00:00:02+00:00", "published_display": "08 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "The article concerns the enterprise value to EBITDA forward metric for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). It appears to be a financial data snippet or a preliminary page from TradingView, indicating that specific financial data for this metric would be displayed. The con", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:41:13", "published_display": "07 Jul 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. \u2013 BOATS:OLMA", "summary": "This article provides financial information for Olema Pharmaceuticals, Inc. (OLMA), specifically focusing on its enterprise value to EBITDA forward. The data is presented within the TradingView platform, noting that the market is closed and no trades have occurred for the company", "url": "https://www.tradingview.com/symbols/BOATS-OLMA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:39:44", "published_display": "07 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article provides a specific financial metric, \"Enterprise value to revenue forward,\" for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA). It indicates that the value for this metric is currently unavailable or not specified, only noting the period, value, change, and percentage c", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:11:54", "published_display": "06 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Olema Pharmaceuticals, Inc. \u2013 NASDAQ:OLMA", "summary": "This article provides financial information for Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), focusing on its forward price to sales metric. It highlights that the data for this financial indicator is contributed by human analysis, suggesting a qualitative aspect to the valuation. ", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T06:10:06", "published_display": "06 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24", "summary": "LifeSci Capital has reiterated its Buy rating for Olema Pharmaceuticals (OLMA.US), maintaining a target price of $24. This indicates continued confidence from the firm in the company's stock performance and future prospects.", "url": "https://www.moomoo.com/news/post/72419265/lifesci-capital-maintains-olema-pharmaceuticals-olmaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-03T06:39:44", "published_display": "03 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced that it granted stock options to eight new employees to purchase 215,800 shares of common stock, effective July 1, 2026. These inducement grants were made under the Company's 2022 Inducement Plan in accordance with Nasdaq Listi", "url": "https://www.manilatimes.net/2026/07/03/tmt-newswire/globenewswire/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2377819", "source_name": "The Manila Times", "published_at": "2026-07-03T05:40:16", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Olema Pharmaceuticals (OLMA) A Bargain After Its Russell Index Additions?", "summary": "Olema Pharmaceuticals (OLMA) has been added to several Russell growth benchmarks, increasing its visibility to institutional investors. Despite a recent mix of share price volatility, the company's valuation, based on a discounted cash flow model, suggests it is significantly und", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-olema-pharmaceuticals-olma-a-bargain-after-its-russell-in", "source_name": "Simply Wall Street", "published_at": "2026-07-03T01:40:46", "published_display": "03 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology awards 215,800 options to eight new employees", "summary": "Olema Oncology (Nasdaq: OLMA) announced it granted stock options to eight new employees to purchase an aggregate of 215,800 shares of common stock, effective July 1, 2026. These inducement awards were made under its 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635", "url": "https://www.stocktitan.net/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-lcfevi8yty7j.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:46", "published_display": "02 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index Inclusion - Has The Bull Case Changed?", "summary": "Olema Pharmaceuticals (OLMA) has seen a 22% stock increase following its inclusion in multiple Russell Growth Benchmarks, including the Russell 2000, 2500, and 3000 indices. While this inclusion boosts visibility and trading liquidity, the company's investment narrative remains f", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/olema-pharmaceuticals-olma-is-up-220-after-broad-russell-gro", "source_name": "Simply Wall Street", "published_at": "2026-07-01T04:09:20", "published_display": "01 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPcTJmZFN1LUItQlFqTm5qVTMtZTdtVmtzWGh0R1R1UEcwc05wLVlTMkZNS0ZCeW5BM3V6RUF6UF9kQmhUUEl0bVV2UmY1TThtMl9ickx3SC1sUjBMYjg1QkI1Q19xZ3ZLUlBZYWlNWk5lcGRVeC0xRnlUNlVfb05ZMHZBTDk0X2RaUE95RnQwSXRhMm96ZUNITU1tdjJrTnJQMzVHOQ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark", "summary": "Olema Pharmaceuticals, Inc. (NasdaqGS:OLMA) has been added to the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent developments for the company, including presentations at healthcare conferences and clinical trial collaborations for its experimental ca", "url": "https://www.marketscreener.com/news/olema-pharmaceuticals-inc-nasdaqgs-olma-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc8bf723", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:13:00", "published_display": "29 Jun 2026 17:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA)", "summary": "This article provides an overview of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, key financial metrics, and company information. The article also answers ", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:35", "published_display": "26 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OLMA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "Olema Pharmaceuticals, Inc. (OLMA) has a current stock price of $11.43, with analysts providing a 1-year price forecast ranging from $23.00 to $62.00, and a consensus target of $40.70. The company's stock has seen significant volatility, with a 143.71% increase over the last year", "url": "https://www.tradingview.com/symbols/NASDAQ-OLMA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:40:35", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51", "summary": "Olema Pharmaceuticals director Harmon Cyrus was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options vest in 12 equal monthly installments beginning June 18, 2026, contingent on continued service, or fully vest at the next", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-ba93150fbec9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:40:35", "published_display": "24 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51", "summary": "Olema Pharmaceuticals director Graham G. Walmsley was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments beginning June 18, 2026, or fully on the date of Olema's next annual sto", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-63bb7cde30f0.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:12:07", "published_display": "24 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young", "summary": "Olema Pharmaceuticals (NASDAQ: OLMA) stockholders approved the election of four Class III directors, an advisory executive compensation program, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year at their annual", "url": "https://www.stocktitan.net/sec-filings/OLMA/8-k-olema-pharmaceuticals-inc-reports-material-event-985158c2578c.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:12:07", "published_display": "24 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price", "summary": "Olema Pharmaceuticals director Cynthia M. Butitta was granted 29,500 stock options at an exercise price of $9.51 per share. These options serve as compensation and will vest in 12 equal monthly installments starting June 18, 2026, provided she continues her service. Any unvested ", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-a16d317b5516.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:12:07", "published_display": "24 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (OLMA) director receives 29,500 options at $9.51 strike price", "summary": "Olema Pharmaceuticals director Sandra Horning was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. The options will vest in 12 equal monthly installments starting June 18, 2026, contingent on her continuous service, with any unves", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-1d03cac55e35.html", "source_name": "Stock Titan", "published_at": "2026-06-24T01:09:50", "published_display": "24 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51", "summary": "Olema Pharmaceuticals director Garland J. Scott was granted 29,500 stock options with an exercise price of $9.51 per share, expiring on June 18, 2036. These options vest in 12 equal monthly installments starting June 18, 2026, contingent on Scott's continuous service. This grant ", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-303ea7dcb677.html", "source_name": "Stock Titan", "published_at": "2026-06-24T01:09:50", "published_display": "24 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price", "summary": "Olema Pharmaceuticals director Andrew Rappaport was granted 29,500 stock options at an exercise price of $9.51 per share, as part of his compensation. These options, which expire on June 18, 2036, vest in 12 equal monthly installments starting June 18, 2026, or fully on the next ", "url": "https://www.stocktitan.net/sec-filings/OLMA/form-4-olema-pharmaceuticals-inc-insider-trading-activity-0651621136c6.html", "source_name": "Stock Titan", "published_at": "2026-06-24T01:09:50", "published_display": "24 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com", "summary": "This article announces the filing of Form 4 for Olema Pharmaceuticals Inc. on June 23. It notes that the company's stock, OLMA, showed a 5.79% increase and includes various financial market data and related news. The content is primarily a brief announcement paired with general m", "url": "https://ng.investing.com/news/stock-market-news/form-4-olema-pharmaceuticals-inc-for-23-june-93CH-2571070", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T22:32:00", "published_display": "23 Jun 2026 22:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNaWpsU0VycWdrSmtfblhZa3BPLTY1aUJOTkVXRUkzM2xiNUlvYnhCcG5ha1REeFRBYUltUXRqd3RyVVZrZ1V5VEhKV2hjNUwweUY2SUUxNFduTFIyQmp4WnBEb0pIQWVNUmN0cDZtbENmWXNNZ0NXQlQ0V04xUm9tVURyczlMN1M1aUNOUXZRcE16eEpyTENMUFBjekxRZ29iQklJbHJWbUZCcTEtSE51aHQ3d0R1Znlvd0dV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema (NASDAQ: OLMA) awards director 29,500 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeDFiTjFCS3ZuT1N2MXJ3UHQ0eHFXVWNLcGp0NmRSQzMzN2xuRlJVV1dZVnM3TTZ4UkR1czhZUzA5Vmt0aVpqWEpacHp4ZFV2c2hhZnp3VzBaWFN6SW9sU05iUDdnbFYzZUp1UXVNSlZYREJBWUtabXhhZ3pjRmxxamxiWnhsYWRjMWNla2JNb2U0TFFyY1JjN2QtVkVKM0Z4WFl0eEpKb3p2Q1Vaa3VMWGtFMDdza29IbjJZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbFBjNkNwc2laMnp5U3Q5YTBwclRpMjEyTzNoOU9jek9WVEZROEt6b2NSbXBVYkpabEFjVU1Ed2YtZnlfOTNHb3dBOFA4R01pSGhOWjF0MkVmeXEzVVdGeGR4T2hrSkI0NFhHWlphMy1lSTNJM1BONmpCTjkzeGZwVEloc1JEUDZfRE9hV2tCSVVDNTBtVi1ESUlHallOaDJ4aGpoU2lR?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-pharmaceuticals-bayer-collaborate-test-115457083.html", "source_name": "MT Newswires", "published_at": "2026-05-26T11:54:57+00:00", "published_display": "26 May 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA\u00ae (darolutamide) in Metastatic Castration-Resistant Prostate Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-oncology-announces-clinical-trial-110000261.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema\u2019s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-op-3136-data-draw-190553267.html", "source_name": "Simply Wall St.", "published_at": "2026-05-25T19:05:53+00:00", "published_display": "25 May 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study", "summary": "", "url": "https://finance.yahoo.com/m/bc714b6d-d579-325f-926d-86b16217feaa/olema-oncology-sees-early.html", "source_name": "Stocktwits", "published_at": "2026-05-22T13:06:31+00:00", "published_display": "22 May 2026 13:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-oncology-announces-encouraging-initial-210000497.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:00:00+00:00", "published_display": "21 May 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/olema-oncology-participate-upcoming-investor-203000735.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:30:00+00:00", "published_display": "19 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema: The Market Overreacted To Roche's SERD Failure", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQT214czFUb1hzdURyZVRwRnZBZWItLXVIZDRGbDFpOFJQb3Y1TG80NHhacmRUcVRsdXZNRGd1ZmFLU0lzR28wcWdQT3p0SGFSY2FBSEoxV1NtbzdIOFdUM0ZnV3IyWGxtRWZ4N0hOQUZ2VEFuTmE0d2x4ZVZHZ3hqdnNuanVpWHJiWGVKeGFKX2xiOVAyWkxZ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdjB0TWhYaGVXczNnQkNiSzNHbmc0WG1maXRFeTBEWWwyMFVlZ2J2bExmallVZnR0YTgzN2NGOWZ2b0RpSXNGS3AzUTh4ZHJCN0xTZUcxRVZKeUlhTS1IQzFiMXUwb3NQcDVYeWhEQW5aUWJTc0xUbFk5eDR2bWNkQjVHeTFMc05oMV8tZEJITDg1TThMTllhZkdCeHcxMUFib2NxVE52dDdKZw?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQcnBMVkV2YXNJWTlvbE9ja0FMY0RnLThneUNFRDlRZzBDZEJCcE5xQmQ3NlZQZUxOMFBfX0ZnVUhpc3dRM2xWYUFKQXFrdnJHY29RdzBIQ1RWajFDSUlFaTk2aWJEbUJXZGNneGxpQW9XWVU3OHNPdUlIM0xIV0lTN2VtZmx3U1JW?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNdHJHQ2lpQ1U3cDN4V0ZVdk5FWTd0N0JPZnBueXNtLXBIMlFUa0VnMExnM0NBU09hX19qaDhjLTUxZ2dvZWpPSG9YODEwMjQ1VGZHWHU2TkdBUXJqdU9UWjF2VTRrNUF6OWhvX1BaMm85MUs4MVBNQWxNbG5iSWptcF9GOGFvTDBKa3pSakQ4Y2k?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After A 348% One\u2011Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQdFZWbXRZUEhtU3ZrRlk3cmp6VHd0V0FmM3RzaHo5NzV2MTEtWjdNa01rYWhDNkxxSmZKNW1sSVFyTWJLalNfWWVBRU9YQTNwRlh5ajM2RC02cHdaNEtqcnFYa2YzZDNqY0VUajRjeEhDd0t3Q3ZkQnQzQTROVFVaQ0ZwRDA2anlILThIcjFB?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTUZCSjYtVGN3dXFENk4yNkxFTzRhYnZVRDN5VWdwSmstZFktWmwySlIwSmV0OFIxWmQtQy1hMmZqcFdhaHF6RnB3b0QyMmtYU2pJTFNaWU9UOFo1WTU2OVVlRVFGTktTbmNzNTZwbi1adXQ3cEVPQS1LQ3NVM3dJa1lnYzd6aGY3al9oWXNnZWo5aVdibHczOW5R?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPQ2xVdzJaNEZIb0FDSk1Bdmg2UFUzRXFJTU1wT216YVRpVkVQRnR3THYteEZtb1ZVSGtFcUUzaHo5SEl6Y1JCWjQzd3d4YU1jMFc0a3ZiWEVDNVl3a0pTMlQ4eFdfVFRjemVXLU92ZTZPMmQ0Nm5FMG13Uk9IRUEzamdJTTdxMDYzOWc?oc=5", "source_name": "Market source", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals Plans Public Offering of Common Stock to Support Breast Cancer Therapy Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQOG9vZENyV0NDMHJpeFhhUXhfV2dWZzAzdkUzZnUzWG42ZEM5UDRvTzQxdTFWY1drdkJPdm4wTUVmTXhiU2xPNWhtVHlPTVZzV3czUU4zRmw2MV9KNFMwRDVYb3k3NV9nRHBSTDAtV2tNaS1fbnpNR2llS005ZlUwSTZmOTVRbXN0cTVMZ2UxZ3ZXbThlNzRKaC1vZFNzbmlIT3FQZ045U2ZoWkJycFlaZVZYNHZrdWh3RDRrOVdQNmlTZy12VDhIaWxnNGZ0WVNPcWZJ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceutical CEO Sean Bohen on the fight to end breast cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNbTVhZERVSzhwMGkxYXJoUWtkUFlhemFYMWgyRnlOdEVpOVBhOU5Md24zYmN3bXVia0VIMWRGM0JfWFBldjhJQ1BSLXg3Y3F6X01DZmF6VUNxRkIxcS1YaDlfdWl2dm5fRVo2d1BYSy0wQzB0X0tJempJTVc4NG42dUpCTFpkRjVESWc3TW1EbFc5Y1ZybXFtSG1JYlFUa1lVaXc2dzVVVWJZNGdaWGtfLUlB?oc=5", "source_name": "CNBC", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE82ek9WWTJlSE9XdHFKRWlQWHNGLUNnbFNiZnF0OFB0YlBwTlZUa3VMdVhUdWM5QTllQlY1MjJ6VmRGZzZTRGxvX1hmUmFjeWcxbHA4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:59:55+00:00", "published_display": "25 Apr 2025 01:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Olema Oncology Announces New Clinical Trial Collaboration", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-12-02T08:00:00+00:00", "published_display": "02 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 57, "sentiment_summary": {"positive": 12, "negative": 2, "neutral": 43, "score": 53, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 21.05, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 11.47, "latest_week": "2026-07-17", "one_week_move": -3.7, "four_week_move": 20.6, "twelve_week_move": -26.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.181702, "market_dynamics_buy_signal": false, "relative_strength": -32.865671, "fair_value_gap": -1.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.0535, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.7% over one week, +20.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 9}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "MarketBeat", "count": 2}, {"label": "Simply Wall Street", "count": 2}, {"label": "Quartr", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.7% over one week, +20.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why"}], "updated_at": "2026-07-18T21:58:34.595396+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}